LFSC F/m Emerald Life Sciences Innovation ETF
ETF on NASDAQ (US) · Actively managed · Listing
Most notable sale · Guardant Health, Inc.
Guardant Health, Inc. cut by 32%
Shares went from 44,694 to 30,287 ($5.80M → $4.82M). Now 3.8% of the portfolio. Estimated trade $2.29M.
Most notable buy · BillionToOne, Inc.
BillionToOne, Inc. raised by 85%
Shares went from 29,023 to 53,729 ($2.87M → $4.87M). Now 3.9% of the portfolio. Estimated trade $2.24M.
Largest holding: Travere Therapeutics, Inc., cut 3%, 165,892 shares ($11.0M).
| Current positions Top 10 | % of book |
|---|---|
| Travere Therapeutics, Inc. TVTX $11.0M · −3% sh | 8.7% |
| Corcept Therapeutics Incorporated CORT $8.49M · +3% sh | 6.7% |
| Spyre Therapeutics, Inc. SYRE $8.46M · +3% sh | 6.7% |
| LivaNova PLC LIVN $8.35M · +3% sh | 6.6% |
| Cogent Biosciences, Inc. COGT $8.18M · +3% sh | 6.5% |
| Mirum Pharmaceuticals, Inc. MIRM $5.46M · +9% sh | 4.3% |
| BillionToOne, Inc. BLLN $4.87M · +85% sh | 3.9% |
| Guardant Health, Inc. GH $4.82M · −32% sh | 3.8% |
| Cytokinetics, Incorporated CYTK $4.41M · +44% sh | 3.5% |
| United Therapeutics Corporation UTHR $4.14M · +3% sh | 3.3% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 98.4% |
| Technology | 1.2% |
| Unclassified | 0.4% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 69.0% |
| Medical Devices | 16.2% |
| Diagnostics & Research | 8.9% |
| Medical Care Facilities | 3.0% |
| Health Information Services | 1.3% |
| Software - Application | 1.2% |
| Unclassified | 0.4% |
| Initiations 2 | Value |
|---|---|
| Praxis Precision Medicines, Inc. PRAX 1.0% of portfolio | $1.24M |
| Replimune Group, Inc. REPL 0.5% of portfolio | $695K |
| Increases 31 | Change |
|---|---|
| BillionToOne, Inc. BLLN $2.87M → $4.87M | +85% |
| Cytokinetics, Incorporated CYTK $3.32M → $4.41M | +44% |
| Axsome Therapeutics, Inc. AXSM $2.98M → $3.85M | +52% |
| NeoGenomics, Inc. NEO $453K → $1.53M | +99% |
| ICU Medical, Inc. ICUI $2.20M → $3.49M | +24% |
| Alphatec Holdings, Inc. ATEC $600K → $1.40M | +93% |
| Mirum Pharmaceuticals, Inc. MIRM $5.17M → $5.46M | +9% |
| Corcept Therapeutics Incorporated CORT $5.03M → $8.49M | +3% |
| Spyre Therapeutics, Inc. SYRE $6.73M → $8.46M | +3% |
| LivaNova PLC LIVN $7.47M → $8.35M | +3% |
| Cogent Biosciences, Inc. COGT $7.91M → $8.18M | +3% |
| United Therapeutics Corporation UTHR $4.37M → $4.14M | +3% |
| Reductions 5 | Change |
|---|---|
| Guardant Health, Inc. GH $5.80M → $4.82M | −32% |
| Trevi Therapeutics, Inc. TRVI $3.27M → $3.26M | −15% |
| F/m Ultrashort Treasury Inflat RBIL $1.14M → $564K | −50% |
| Travere Therapeutics, Inc. TVTX $8.05M → $11.0M | −3% |
| Dianthus Therapeutics, Inc. DNTH $3.24M → $3.41M | −7% |
| Terminations 3 | Change |
|---|---|
| Xeris Biopharma Holdings, Inc. XERS was $1.28M | −100% |
| BridgeBio Pharma, Inc. BBIO was $1.23M | −100% |
| Integer Holdings Corporation ITGR was $1.20M | −100% |
The other 19 increases
Nektar Therapeutics (+3%), TransMedics Group, Inc. (+3%), Savara, Inc. (+3%), Veradermics, Incorporated (+3%), Viridian Therapeutics, Inc. (+3%), Palvella Therapeutics, Inc. (+3%), Twist Bioscience Corporation (+3%), Corvus Pharmaceuticals, Inc. (+3%), CeriBell, Inc. (+3%), Hinge Health, Inc. (+3%), Waystar Holding Corp. (+3%), Aveanna Healthcare Holdings Inc. (+3%), Globus Medical, Inc. (+3%), RadNet, Inc. (+3%), Lumexa Imaging Holdings, Inc. (+3%), Korro Bio, Inc. (+3%), Wave Life Sciences, Inc. (+3%), Insmed Incorporated (+3%), Alamar Biosciences, Inc. (+3%)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the prospectus filed Jan 5, 2026.
The investment objective of the F/m Emerald Life Sciences Innovation ETF (the "Fund") is to seek long-term capital appreciation.
Principal investment strategies
The Fund is an actively managed exchange-traded fund ("ETF") and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust (the "Sub-Adviser"), the Fund's investment sub-adviser, under the supervision of the Adviser. The Fund intends to identify and invest in unique growth opportunities within the life sciences universe by following scientific, technological and/or strategic innovation. The Sub-Adviser believes that innovative companies are those developing new products or reinventing/redesigning existing products/services, thereby generating value for their customers, creating a competitive advantage and/or driving business growth. The Sub-Adviser applies this theme of innovation by using its proprietary 10-step research process to identify companies that the Sub-Adviser believes are substantially focused on or are expected to substantially benefit from one or more of the following criteria: ● Technological Advancement: In its simplest terms, technological advancement in life science companies involves the translation of innovative science into new products and/or services that improve the lives of consumers. ● Market Disruption: Market disruption occurs when a company uses new or enhanced technology, manufacturing, marketing, distribution or service delivery approaches to challenge conventional business models, markets, or industries. ● Artificial Intelligence (AI) in life science: AI plays a key role in many areas within the Life Sciences industry, utilized by companies that build new AI products and those that most effectively use AI to enhance their business. The Sub-Adviser intends to apply the above principles to the following life science fields, among others: Biotechnology. Biotechnology companies translate innovative science into therapeutic applications. This is done by a variety of treatment modalities including small molecules, antibodies, nucleic acids, or a combination of several of these treatment modalities. Pharmaceutical. Pharmaceutical companies develop, produce and distribute medications. Medical Diagnostics. Medical Diagnostic companies play a vital role in diagnosing and monitoring medical conditions. These can be an imaging test using an X-Ray, CT, MRI etc. or a laboratory performed test on a sample, among others. Molecular Diagnostic tests are used to help identify a disease or the risk of developing a disease, such as cancer, by studying molecules, such as DNA, RNA, and proteins, in a tissue or fluid sample. Molecular diagnostics may also be used to help plan the treatment for a disease, look for recurrence of a disease, or find out how well a treatment is working. This can take the form of tests for specific biomarkers, genetic tests for predisposition to a disease or condition, tumor sequencing tests or liquid biopsy tests. Medical Devices. Medical devices companies produce instruments, apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for a health purpose. Healthcare Services. Healthcare services companies provide care and/or services in multiple settings, ranging from hospital services to urgent care clinics to newer modes of engagement with telemedicine. Healthcare Technologies ("Health-tech"). Health-tech companies incorporate novel technologies that enable the delivery of technology-enabled healthcare products and services that can be delivered or consumed outside of a hospital or physician's office or enhance overall outcomes through artificial intelligence or machine learning. Synthetic Biology. Synthetic Biology is a scientific field that uses engineering principles to design and modify organisms and biological systems.
Management and Contact
- Adviser
- Fm Investments LLC
- Sub-adviser
- Emerald Mutual Fund Advisers Trust
- Phone
- 1-800-617-0004
- Website
- emeraldetfs.com
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 30, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
39 lines, 38 linked, weights sum to 100.04% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | TVTX US89422G1076 | Equity | 165,892 | −4,822 | 8.71% | $ 10.995M |
| Corcept Therapeutics Inc | CORT US2183521028 | Equity | 74,897 | +2,443 | 6.72% | $ 8.49M |
| Spyre Therapeutics Inc | SYRE US00773J2024 | Equity | 94,677 | +3,089 | 6.70% | $ 8.457M |
| LivaNova PLC | LIVN GB00BYMT0J19 | Equity | 104,627 | +3,415 | 6.61% | $ 8.35M |
| Cogent Biosciences Inc | COGT US19240Q2012 | Equity | 233,781 | +7,639 | 6.48% | $ 8.182M |
| Mirum Pharmaceuticals Inc | MIRM US6047491013 | Equity | 55,641 | +4,730 | 4.32% | $ 5.456M |
| Billiontoone Inc | BLLN US0901681058 | Equity | 53,729 | +24,706 | 3.86% | $ 4.872M |
| Guardant Health Inc | GH US40131M1099 | Equity | 30,287 | −14,407 | 3.81% | $ 4.816M |
| Cytokinetics Inc | CYTK US23282W6057 | Equity | 62,243 | +18,975 | 3.50% | $ 4.414M |
| United Therapeutics Corp | UTHR US91307C1027 | Equity | 8,102 | +261 | 3.27% | $ 4.135M |
| Axsome Therapeutics Inc | AXSM US05464T1043 | Equity | 19,398 | +6,675 | 3.05% | $ 3.851M |
| Nektar Therapeutics | NKTR US6402683063 | Equity | 52,589 | +1,713 | 2.97% | $ 3.754M |
| TransMedics Group Inc | TMDX US89377M1099 | Equity | 43,305 | +1,411 | 2.91% | $ 3.675M |
| Savara Inc | SVRA US8051111016 | Equity | 673,019 | +21,995 | 2.87% | $ 3.628M |
| VeraDermics Inc | MANE US9229671048 | Equity | 36,765 | +1,197 | 2.87% | $ 3.618M |
| ICU Medical Inc | ICUI US44930G1076 | Equity | 20,198 | +3,971 | 2.77% | $ 3.493M |
| Dianthus Therapeutics Inc | DNTH US2528281080 | Equity | 32,291 | −2,593 | 2.70% | $ 3.41M |
| Trevi Therapeutics Inc | TRVI US89532M1018 | Equity | 196,667 | −34,935 | 2.59% | $ 3.265M |
| Viridian Therapeutics Inc | VRDN US92790C1045 | Equity | 137,759 | +4,498 | 2.53% | $ 3.19M |
| Palvella Therapeutics Inc | PVLA US6979471090 | Equity | 17,830 | +576 | 2.15% | $ 2.721M |
| Twist Bioscience Corp | TWST US90184D1000 | Equity | 18,448 | +598 | 2.03% | $ 2.564M |
| Corvus Pharmaceuticals Inc | CRVS US2210151005 | Equity | 170,887 | +5,582 | 1.90% | $ 2.399M |
| Ceribell Inc | CBLL US15678C1027 | Equity | 91,335 | +2,981 | 1.73% | $ 2.19M |
| Hinge Health Inc | HNGE US4333131039 | Equity | 18,179 | +589 | 1.33% | $ 1.683M |
| NeoGenomics Inc | NEO US64049M2098 | Equity | 85,594 | +42,523 | 1.21% | $ 1.533M |
| Waystar Holding Corp | WAY US9467841055 | Equity | 57,012 | +1,857 | 1.18% | $ 1.493M |
| Aveanna Healthcare Holdings In | AVAH US05356F1057 | Equity | 109,347 | +3,568 | 1.16% | $ 1.467M |
| Alphatec Holdings Inc | ATEC US02081G2012 | Equity | 149,732 | +72,346 | 1.11% | $ 1.403M |
| Globus Medical Inc | GMED US3795772082 | Equity | 16,802 | +544 | 1.08% | $ 1.367M |
| Praxis Precision Medicines Inc | PRAX US74006W2070 | Equity | 3,548 | new +3,548 | 0.98% | $ 1.243M |
| RadNet Inc | RDNT US7504911022 | Equity | 15,398 | +499 | 0.92% | $ 1.167M |
| Lumexa Imaging Holdings Inc | LMRI US5502491062 | Equity | 98,183 | +3,206 | 0.91% | $ 1.146M |
| Korro Bio Inc | KRRO US5009461089 | Equity | 64,974 | +2,119 | 0.64% | $ 811.525K |
| Wave Life Sciences Inc | WVE US94352A1043 | Equity | 157,141 | +5,133 | 0.61% | $ 769.991K |
| Insmed Inc | INSM US4576693075 | Equity | 6,248 | +198 | 0.60% | $ 761.131K |
| Replimune Group Inc | REPL US76029N1063 | Equity | 45,400 | new +45,400 | 0.55% | $ 694.62K |
| F/m Ultrashort Treasury Inflat | RBIL US74933W2136 | Fund | 11,287 | −11,464 | 0.45% | $ 564.011K |
| Alamar Biosciences Inc | ALMR US0109111056 | Equity | 9,757 | +315 | 0.24% | $ 297.979K |
|
U.S. Bank Money Market Deposit Account
|
USBFS04 8AMMF0A92 | Money market | 571.8 | +368.89 | 0.00% | $ 571.80 |
Trades May 31, 2026 to Aug 31, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| Guardant Health Inc | GH | Sold | 44,694 | 30,287 | −14,407 | $ -2.291M |
| Billiontoone Inc | BLLN | Bought | 29,023 | 53,729 | +24,706 | $ 2.24M |
| Cytokinetics Inc | CYTK | Bought | 43,268 | 62,243 | +18,975 | $ 1.346M |
| Axsome Therapeutics Inc | AXSM | Bought | 12,723 | 19,398 | +6,675 | $ 1.325M |
| Xeris Biopharma Holdings Inc | XERS | Closed | 207,543 | — | −207,543 | $ -1.278M |
| Praxis Precision Medicines Inc | PRAX | New | — | 3,548 | +3,548 | $ 1.243M |
| Bridgebio Pharma Inc | BBIO | Closed | 18,534 | — | −18,534 | $ -1.228M |
| Integer Holdings Corp | ITGR | Closed | 13,436 | — | −13,436 | $ -1.201M |
| NeoGenomics Inc | NEO | Bought | 43,071 | 85,594 | +42,523 | $ 761.587K |
| Replimune Group Inc | REPL | New | — | 45,400 | +45,400 | $ 694.62K |
| ICU Medical Inc | ICUI | Bought | 16,227 | 20,198 | +3,971 | $ 686.784K |
| Alphatec Holdings Inc | ATEC | Bought | 77,386 | 149,732 | +72,346 | $ 677.882K |
| Trevi Therapeutics Inc | TRVI | Sold | 231,602 | 196,667 | −34,935 | $ -579.921K |
| F/m Ultrashort Treasury Inflat | RBIL | Sold | 22,751 | 11,287 | −11,464 | $ -572.856K |
| Mirum Pharmaceuticals Inc | MIRM | Bought | 50,911 | 55,641 | +4,730 | $ 463.777K |
| Travere Therapeutics Inc | TVTX | Sold | 170,714 | 165,892 | −4,822 | $ -319.602K |
| Corcept Therapeutics Inc | CORT | Bought | 72,454 | 74,897 | +2,443 | $ 276.914K |
| Spyre Therapeutics Inc | SYRE | Bought | 91,588 | 94,677 | +3,089 | $ 275.94K |
| Dianthus Therapeutics Inc | DNTH | Sold | 34,884 | 32,291 | −2,593 | $ -273.847K |
| LivaNova PLC | LIVN | Bought | 101,212 | 104,627 | +3,415 | $ 272.551K |
| Cogent Biosciences Inc | COGT | Bought | 226,142 | 233,781 | +7,639 | $ 267.365K |
| United Therapeutics Corp | UTHR | Bought | 7,841 | 8,102 | +261 | $ 133.209K |
| Nektar Therapeutics | NKTR | Bought | 50,876 | 52,589 | +1,713 | $ 122.274K |
| TransMedics Group Inc | TMDX | Bought | 41,894 | 43,305 | +1,411 | $ 119.752K |
| Savara Inc | SVRA | Bought | 651,024 | 673,019 | +21,995 | $ 118.553K |
| VeraDermics Inc | MANE | Bought | 35,568 | 36,765 | +1,197 | $ 117.797K |
| Viridian Therapeutics Inc | VRDN | Bought | 133,261 | 137,759 | +4,498 | $ 104.174K |
| Palvella Therapeutics Inc | PVLA | Bought | 17,254 | 17,830 | +576 | $ 87.892K |
| Twist Bioscience Corp | TWST | Bought | 17,850 | 18,448 | +598 | $ 83.122K |
| Corvus Pharmaceuticals Inc | CRVS | Bought | 165,305 | 170,887 | +5,582 | $ 78.371K |
| Ceribell Inc | CBLL | Bought | 88,354 | 91,335 | +2,981 | $ 71.484K |
| Hinge Health Inc | HNGE | Bought | 17,590 | 18,179 | +589 | $ 54.518K |
| Waystar Holding Corp | WAY | Bought | 55,155 | 57,012 | +1,857 | $ 48.616K |
| Aveanna Healthcare Holdings In | AVAH | Bought | 105,779 | 109,347 | +3,568 | $ 47.883K |
| Globus Medical Inc | GMED | Bought | 16,258 | 16,802 | +544 | $ 44.265K |
| RadNet Inc | RDNT | Bought | 14,899 | 15,398 | +499 | $ 37.834K |
| Lumexa Imaging Holdings Inc | LMRI | Bought | 94,977 | 98,183 | +3,206 | $ 37.414K |
| Korro Bio Inc | KRRO | Bought | 62,855 | 64,974 | +2,119 | $ 26.466K |
| Wave Life Sciences Inc | WVE | Bought | 152,008 | 157,141 | +5,133 | $ 25.152K |
| Insmed Inc | INSM | Bought | 6,050 | 6,248 | +198 | $ 24.12K |
| Alamar Biosciences Inc | ALMR | Bought | 9,442 | 9,757 | +315 | $ 9,620.10 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up